GLP-1 receptor agonist

Phase 3Small molecule

Boehringer Ingelheim

GLP-1 receptor agonist is one of 279 small molecule programs targeting Morbid Obesity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

278

Competitors

Pipeline

Status by Indication[3][1]

Indication

Morbid ObesityRecruiting

Total Neoadjuvant TherapyNot yet recruiting

Weight LossActive, not recruiting

Diabetes MellitusActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

ObesityActive, not recruiting

Polycystic Ovary SyndromeNot yet recruiting

Gene PolymorphismRecruiting

Type 2 DiabetesCompleted

Morbid ObesityPhase 3

Recruiting

Total Neoadjuvant TherapyPhase 2

Not yet recruiting

Weight LossPreclinical

Active, not recruiting

Diabetes MellitusPreclinical

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

ObesityPreclinical

Active, not recruiting

Polycystic Ovary SyndromePreclinical

Not yet recruiting

Gene PolymorphismPreclinical

Recruiting

Type 2 DiabetesPhase 3

Completed

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Amgen

Phase 3

7 2

Retatrutide

Eli Lilly

Phase 3

6 3

NNC0487-0111

Novo Nordisk

Phase 3

11 4

GLP-1 receptor agonist

Boehringer Ingelheim

Phase 3

2 5

Cagrisema

Novo Nordisk

Phase 3

5 6

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

1 7

Zenagamtide

Novo Nordisk

Phase 3

3 8

Berobenatide

Pfizer

Phase 3

3 9

Ribupatide

KKailera

Phase 3

3 10

PF-08653944

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Type 2 Diabetes

NCT06715514

Q4 2027

Active, not recruiting

Obesity

NCT07115069

N/ANot yet recruiting

Obesity

NCT06775093

Q1 2028

N/ARecruiting

Gene Polymorphism

NCT06256419

Q3 2028

Phase 2Not yet recruiting

Total Neoadjuvant Therapy

NCT07314528

Clinical

Trials by Indication[1]

Type 2 Diabetes6 trials

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Completed·GGRADE Study Group·Phase 3·NCT01794143·7,850 enrolled

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

Completed·AAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari··NCT06120556·130 enrolled

Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

Completed·PPegBio Co., Ltd.·Phase 3·NCT04504396·620 enrolled

Show 3 more trials

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Recruiting·—·Phase 4·NCT05390892·6,000 enrolled

Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin

Unknown status·—··NCT04034524·20,000 enrolled

Effects of Combined Menopausal Hormone Therapy and GLP-1 Receptor Agonist Therapy on Glucose and Energy Homeostasis in Early Postmenopausal Women With or at Risk of Diabetes

Active, not recruiting·LLia Bally·Preclinical·NCT06715514·96 enrolled

GLP-12 trials

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

Terminated·UUniversity of Mississippi Medical Center·Phase 2·NCT04964388·5 enrolled

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Recruiting·—··NCT07309094·250 enrolled

Gene Polymorphism2 trials

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·N/A·NCT06256419·300 enrolled

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

Completed·TThe Affiliated Hospital of Xuzhou Medical University·N/A·NCT05037045·338 enrolled

Obesity2 trials

Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity

Not yet recruiting·PPeking University Third Hospital·N/A·NCT06775093·392 enrolled

Conduct of the REsponses in Function and Outcomes From RYGB vs. Medication Study (REFORM) Study by Research Coordinators

Active, not recruiting·VVanderbilt University Medical Center··NCT07115069·60 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

Completed·PPegBio Co., Ltd.·Phase 3·NCT04504370·273 enrolled

15 more indications

Diabetes Mellitus1 trial

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

Completed·JJose Seijas Amigo··NCT05136287·140 enrolled

Insulin Secretion1 trial

Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients

Unknown status·DDasman Diabetes Institute·Phase 4·NCT04135287·315 enrolled

Metabolism1 trial

Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy

Recruiting·UUniversity of Virginia··NCT06903923·120 enrolled

Microbiota1 trial

Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota

Completed·UUniversity of Tartu··NCT04151849·23 enrolled

Total Neoadjuvant Therapy1 trial

Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer

Not yet recruiting·SSt. James's Hospital, Ireland·Phase 2·NCT07314528·42 enrolled

Cardiovascular1 trial

Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS

Recruiting·—··NCT06889454·120 enrolled

Sts1 trial

Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health

Unknown status·KKing's College London··NCT05492305·20 enrolled

SGLT-2 Inhibitor1 trial

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Completed·UUniversity of Padova··NCT04184947·10,000 enrolled

Chronic Kidney Disease1 trial

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

Completed·LLMC Diabetes & Endocrinology Ltd.··NCT06236672·348 enrolled

Medication1 trial

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

Unknown status·—··NCT05161429·550,000 enrolled

Morbid Obesity1 trial

Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric

Recruiting·UUniversity of Missouri-Columbia·Approved·NCT06132477·150 enrolled

Diabetes Mellitus, Type 21 trial

EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03363464·230,000 enrolled

NAFLD1 trial

Effect of Glucagon-like Peptide -1 Receptor Agonist on Liver Tissue and Plasma Lipids in MASLD

Withdrawn·MMedical College of Wisconsin··NCT06982378

Polycystic Ovary Syndrome1 trial

Effects of GLP-1 Receptor Agonists Combined With Healthy Lifestyle Education Prior to Fertility Treatment on Reproductive Outcomes in Obese Women With Polycystic Ovary Syndrome

Not yet recruiting·PPeking University Third Hospital·Preclinical·NCT07687667·406 enrolled

Cardiovascular-kidney-metabolic Syndrome1 trial

Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation

Completed·CChung Shan Medical University··NCT07465926·451,036 enrolled

Sources

References

[1]
ClinicalTrials.gov — 28 trial records for GLP-1 receptor agonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLP-1 receptor agonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLP-1 receptor agonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Boehringer Ingelheim

GLP-1 receptor agonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Q3 2028

Trials by Indication[1]

Type 2 Diabetes6 trials

GLP-12 trials

Gene Polymorphism2 trials

Obesity2 trials

Safety and Efficacy1 trial

Diabetes Mellitus1 trial

Insulin Secretion1 trial

Metabolism1 trial

Microbiota1 trial

Total Neoadjuvant Therapy1 trial

Cardiovascular1 trial

Sts1 trial

SGLT-2 Inhibitor1 trial

Chronic Kidney Disease1 trial

Medication1 trial

Morbid Obesity1 trial

Diabetes Mellitus, Type 21 trial

NAFLD1 trial

Polycystic Ovary Syndrome1 trial

Cardiovascular-kidney-metabolic Syndrome1 trial

References

Drug Info

Quick Facts

Related News